Navigation Links
Smallpox vaccine alternative identified
Date:1/7/2008

Irvine, Calif., Jan. 7, 2008 University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.

Philip Felgner and Huw Davies with the Department of Medicine found that the modified vaccinia virus Ankara (MVA) produced the same antiviral response in human and animal studies as the current smallpox vaccine, Dryvax. The study is part of a national effort to develop a replacement for the Dryvax vaccine, which causes serious complications in some people. The results are published in the Journal of Virology.

Studies have shown MVA to be a much safer vaccine product that takes advantage of modern technology, Felgner said. We are pleased that our advanced analytical methods may help to bring an effective and safer vaccine to the public.

Smallpox was declared eradicated worldwide in 1980; the last naturally occurring case in the world was in Somalia in 1977. Routine vaccination against smallpox in the U.S. stopped in 1972, and Dryvax production was halted in 1982.

Both Dryvax and MVA are strains of vaccinia virus, which is related to the smallpox virus. The antibodies created by vaccinia virus infection protect a person against a lethal smallpox infection, making it suitable for use as a vaccine. Unlike smallpox virus, vaccinia creates a very mild infection and is completely safe for healthy individuals.

Although Dryvax was effective during the eradication campaign in the 1960s and 70s, its manufacturing methods are outdated by todays standards, and it is also associated with significant risk of adverse reactions for immune-compromised individuals.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, identified MVA as a possible candidate to replace Dryvax. MVA was first developed in the 1970s and has been administered to animal species and humans with little or no adverse side effects.

In the study, Felgner and Davies applied blood serum samples taken from both humans and animals given the MVA or Dryvax vaccines to microarray chips containing more than 200 vaccinia virus proteins, on which they simultaneously studied how the serum antibodies responded to all the vaccinia proteins.

The researchers found that these antibody responses were similar in both the animal and human subjects regardless whether they were given MVA or Dryvax, suggesting that MVA contains antiviral properties similar to those in Dryvax.

This similarity is vital, Davies says, because if a vaccine initiates an immune response in humans that matches the one in animals that are protected against lethal pox viruses, then public health officials will have more confidence that the vaccine will be effective in humans.

This is particularly important for vaccines against lethal infections like smallpox, where human clinical trials cannot be done, he added.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate
2. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Vaccine Stops Alzheimers Brain Tangles
5. Human Papilloma Virus vaccines may decrease chances of oral cancer
6. U.S. Teens Fall Short on Vaccine Coverage
7. Nasal Anthrax Vaccine Proves Effective in Animal Study
8. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
9. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
10. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
11. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Dallas, Texas (PRWEB) , ... May 02, 2016 ... ... Volume 3, Issue 1 of Patient Experience Journal (PXJ), an international, open ... patient experience. With almost half the issue representing international (non-US) based authors, the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s ... eating, mood and anxiety disorders, has rebranded its eating disorder program under a new ... eating disorder treatment facility on May 16. , To celebrate, ERC Chicago will ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... in Huntington Beach, California announced today the release of Grow Healthy Vending’s newly ... is one of the fastest growing healthy vending providers in North America with ...
(Date:5/2/2016)... ... ... This week Omega Institute, a premier nonprofit educational retreat center in New ... is offering a record 370 in-person workshops and new online learning opportunities and ... in or need for the knowledge and skills we’ve been cultivating for nearly 40 ...
(Date:5/2/2016)... ... ... World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February and Chris Mazur, ... being held in London, England this year from June 18-25. At the last WUGC in ... the women’s masters division, and a silver in the women’s division, so Mazur hopes to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life sciences, ... team to bring a wealth of insight to a growing business. ... knowledge. George Phillips joined ArisGlobal in the ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology: